Market Overview

RBC Capital Initiates Epizyme With Outperform


Analysts at RBC Capital initiated coverage on Epizyme Inc (NASDAQ: EPZM) with a Outperform rating.

The target price for Epizyme is set to $40.

Epizyme shares have dropped 29.99 percent over the past 52 weeks, while the S&P 500 index has surged 5.01 percent in the same period.

Epizyme shares fell 2.45 percent to close at $22.71 on Thursday.

Latest Ratings for EPZM

Dec 2020JefferiesDowngradesBuyHold
Nov 2020Morgan StanleyMaintainsOverweight
Aug 2020Morgan StanleyMaintainsOverweight

View More Analyst Ratings for EPZM
View the Latest Analyst Ratings


Related Articles (EPZM)

View Comments and Join the Discussion!

Posted-In: RBC CapitalInitiation Analyst Ratings

Latest Ratings

TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at